Aurobindo Pharma’s arm obtains marketing authorisation from MHRA for biosimilar Zefylti

14 May 2025 Evaluate

Aurobindo Pharma’s wholly owned step-down subsidiary--CuraTeQ Biologics s.r.o. has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Zefylti, its filgrastim biosimilar version. 

Earlier in February 2025, Zefylti had received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ’s second biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1205.95 -6.70 (-0.55%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×